NCT07335432

Brief Summary

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times. The primary outcome was to compare intraoperative blood loss between patients who received intravenous Vitamin C and those who did not, following an abdominal hysterectomy under general anesthesia. Intraoperative estimated blood loss (EBL) was meticulously quantified by weighing surgical gauze and measuring suction canister volumes. The secondary outcomes were to evaluate the potential benefits of Vitamin C administration, including:

  • Reduction in the decline of hematocrit levels after surgery.
  • Reduction of the length of hospital stay

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
3mo left

Started Sep 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Sep 2024Jul 2026

Study Start

First participant enrolled

September 1, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 5, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Expected
Last Updated

January 13, 2026

Status Verified

September 1, 2025

Enrollment Period

11 months

First QC Date

January 5, 2026

Last Update Submit

January 5, 2026

Conditions

Myoma;UterusAdenomyosis of Uterus

Keywords

Vitamin CTotal abdominal hysterectomyBlood loss

Outcome Measures

Primary Outcomes (1)

  • Intraoperative estimate blood loss

    intraoperative

Study Arms (2)

Experimental: Vitamin C

EXPERIMENTAL

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

Dietary Supplement: Vitamin C (Ascorbic Acid)

Placebo

EXPERIMENTAL
Dietary Supplement: Vitamin C (Ascorbic Acid)

Interventions

Vitamin C (Ascorbic Acid)DIETARY_SUPPLEMENT

Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision.

Experimental: Vitamin CPlacebo

Eligibility Criteria

Age20 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female patients who underwent total abdominal hysterectomy
  • No bleeding tendency.
  • No history of anticoagulant or thrombolytic drug use
  • No contraindications to vitamin C supplementation

You may not qualify if:

  • Inability to communicate in the Thai language.
  • Underwent total abdominal hysterectomy due to gynecologic malignancy.
  • Required emergency total abdominal hysterectomy.
  • History of vitamin C supplementation within 2 weeks prior to surgery.
  • History of smoking.
  • Previous abdominal surgery, such as bowel surgery, cesarean section

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen Savang Vadhana Memorial hospital

Si Racha, Changwat Chon Buri, 20110, Thailand

Location

MeSH Terms

Conditions

MyofibromaAdenomyosisHemorrhage

Interventions

Ascorbic Acid

Condition Hierarchy (Ancestors)

Neoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsConnective Tissue DiseasesSkin and Connective Tissue DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

January 5, 2026

First Posted

January 13, 2026

Study Start

September 1, 2024

Primary Completion

July 31, 2025

Study Completion (Estimated)

July 31, 2026

Last Updated

January 13, 2026

Record last verified: 2025-09

Locations

TH(1)